Momentum continues to build in the use of high-efficacy, disease modifying therapies (DMTs) as a first choice for treating multiple sclerosis. How is this being influenced by the availability of anti-CD20s, a new class of DMT? Will future new therapy classes change the paradigm even further?
Ipsos partnered with the HLTH Foundation to shine a light on existing health tech-related inequities in the US and identify opportunities for the industry to address techquity gaps.
Social insights have become a critical component of understanding patients, HCPs, and caregivers – and a key input into developing products and services that meet their needs.
This year’s Digital Doctor is the most illuminating in the series thus far, providing a global view of doctors’ digital and connected health usage through a pre- and post-COVID-19 lens.
Healthcare habits are going through an unprecedented upheaval: a new relationship between health professionals and patients has emerged. This session will help health-care decision-makers with an in-depth understanding of the evolution of their market.
